Optimal designs for phase II/III drug development programs including methods for discounting of phase II results

DOI10.1186/S12874-020-01093-WWikidataQ100511399 ScholiaQ100511399MaRDI QIDQ5978235

Heiko Götte, Marietta Kirchner, Stella Preussler, Meinhard Kieser

Publication date: 9 October 2020

Published in: BMC Medical Research Methodology (Search for Journal in Brave)

Related Items (1)

drugdevelopR

This page was built for publication: Optimal designs for phase II/III drug development programs including methods for discounting of phase II results